Last reviewed · How we verify
NCT05189834: GELSECTAN
GELSECTAN® and Covert Hepatic Encephalopathy
NA trial testing Gelsectan in Covert Hepatic Encephalopathy. Withdrawn.
30 May 2022
Quick facts
| Lead sponsor | Consorci Sanitari de l'Alt Penedès i Garraf |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 11 March 2022 |
| Primary completion | 30 May 2022 |
| Estimated completion | 30 July 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Gelsectan
Conditions studied
- Covert Hepatic Encephalopathy — all drugs for Covert Hepatic Encephalopathy →
Sponsor
Consorci Sanitari de l'Alt Penedès i Garraf — full company profile →
Who can join
Adults 18 to 85, any sex, with Covert Hepatic Encephalopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Randomized crossover pilot clinical trial in which 10 cirrhotic patients with covert hepatic encephalopathy (CHE) will be assigned to take GELSECTAN® (TID) or placebo for 30 days. After a washout period of 15 days, the treatment branches will be interchanged. The objective of the trial is to obtain pilot variances to design a phase II trial, in which the efficacy of the treatment will be tested. As an exploratory objective, the efficacy of the product in the treatment of covert hepatic encephalopathy will be analyzed. Main endpoint Improvement in CHE after 30 days of treatment with GELSECTAN®, measured by the Psychometric hepatic encephalopathy score (PHES)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Future Therapies of Hepatic Encephalopathy.
Buckholz AP, Brown RS. · · 2024 · cited 5× · PMID 38548443 · DOI 10.1016/j.cld.2024.02.002
Verify or expand the search:
- PubMed search for NCT05189834
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Gelsectan
Trials testing the same drug.
- NCT07000383 — Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome · NA · recruiting
Other Consorci Sanitari de l'Alt Penedès i Garraf trials
Trials by the same sponsor.
- NCT07278648 — High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency D · not yet recruiting
- NCT06433739 — Efficacy of a Clinical Algorithm for the Selection of Peripheral Venous Catheters · completed
- NCT07007013 — Impact of Humor Prescription on the Emotional Well-being of Patients With Medically Unexplained Symptoms: A Quasi-experi · NA · active not recruiting
- NCT07285330 — Dietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes · recruiting
- NCT06950151 — Early Detection of Chronic Kidney Disease · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05189834 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Consorci Sanitari de l'Alt Penedès i Garraf
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05189834.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing